Novartis positive Phase 3 Cosentyx data for first time in China

• Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3[1]
• Results strengthen unique position of Cosentyx as a rapid and long-lasting complete treatment of psoriatic disease, with over 200,000 patients treated worldwide[2]
• Data is being presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12[1].

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-data-confirm-rapid-response-and-high-efficacy-of-Cosentyx-in-psoriasis-patients-for-firs-28104095/